未登录

M

Matthew Herder

Dalhousie University

H指数:14

被引数:653

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Competitive Interdependence: A Critical Political Economy of Regulation during the COVID-19 Pandemic.

竞争性相互依存：COVID-19疫情期间监管的关键政治经济学。

Social Science & Medicine

IF5

2025-11-240

PRE

Flexibility over rigor: stakeholder acceptance of the limitations of confirmatory studies following accelerated approval

Health Affairs Scholar

IF0

2025-11-010

OA

Public Sector Innovation and the Constraints of ‘Platform Thinking’: An Account of Johnson & Johnson’s Adenoviral Vector Vaccines

公共部门创新与“平台思维”的约束：强生公司腺病毒载体疫苗的案例研究

Social Science & Medicine

IF5

2025-10-170

PRE

Drug Decriminalization in British Columbia and Changes in Drug Crime and Opioid and Stimulant Harms

不列颠哥伦比亚省的药物非刑事化及其对毒品犯罪、阿片类药物和兴奋剂危害的影响

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

IF55

2025-06-031

PRE

Pharmacare Act does not prescribe universal, public pharmacare

CANADIAN MEDICAL ASSOCIATION JOURNAL

IF11.3

2024-08-112

OAAI

Clinical trial registration and results reporting: a call for transparency, coordination, and meaningful enforcement

CANADIAN MEDICAL ASSOCIATION JOURNAL

IF11.3

2024-05-120

OAAI

How to use the regulatory data from Health Canada for secondary analyses on new drugs, biologics and vaccines

BMJ EVIDENCE-BASED MEDICINE

IF7.6

2023-10-280

OAAI

Extending the US Food and Drug Administration's Postmarket Authorities

JAMA HEALTH FORUM

IF11.3

2023-06-0911

OA

Biopharmaceutical Financialization and Public Funding of Medical Countermeasures (MCMs) in Canada During the COVID-19 Pandemic

INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT

IF5.1

2023-05-271

OAAI

US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeutics

BMJ EVIDENCE-BASED MEDICINE

IF7.6

2023-03-210

PRE

Reducing barriers to accessing administrative data on SARS-CoV-2 vaccination for research

CANADIAN MEDICAL ASSOCIATION JOURNAL

IF11.3

2022-07-176

OAAI

Optimizing the data available on Health Canada's clinical information portal

CANADIAN MEDICAL ASSOCIATION JOURNAL

IF11.3

2021-10-170

OAAI

From sandbox to pandemic: Agile reform of Canadian drug regulation

IF3.4

2021-09-0112

OAAI

Optimizing the data available via Health Canada's clinical information portal

CANADIAN MEDICAL ASSOCIATION JOURNAL

IF11.3

2021-08-225

OAAI

Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19

INTERNATIONAL JOURNAL OF HEALTH SERVICES

IF3.1

2020-12-2117

OAAI

A responsibility to commercialize? Tracing academic researchers' evolving engagement with the commercialization of biomedical research

商业化的责任？追踪学术研究人员对生物医学研究商业化的不断发展的参与

JOURNAL OF RESPONSIBLE INNOVATION

IF4.1

2019-05-0119

PREAI

Canada finally opens up data on new drugs and devices

BMJ-BRITISH MEDICAL JOURNAL

IF42.7

2019-04-177

PREAI

High-strength opioid formulations: the case for a ministerial recall

CANADIAN MEDICAL ASSOCIATION JOURNAL

IF11.3

2018-12-027

OAAI

Reinstitutionalizing transparency at Health Canada

CANADIAN MEDICAL ASSOCIATION JOURNAL

IF11.3

2015-12-222

OAAI

Who will implement WHO's statement on public disclosure of trial results?

IF88.5

2015-06-012

PREAI